Dr. Siefker-Radtke is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161- Is this information wrong?
Education & Training
- University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1999 - 2002
- Tufts Medical CenterResidency, Internal Medicine, 1996 - 1999
- Johns Hopkins University School of MedicineClass of 1996
Certifications & Licensure
- FL State Medical License 2021 - Present
- TX State Medical License 2001 - 2024
- OK State Medical License 2020 - 2021
Clinical Trials
- SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment Start of enrollment: 2000 Dec 01
- Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone Start of enrollment: 2003 Mar 20
- Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant Start of enrollment: 2003 Apr 23
- Join now to see all
Publications & Presentations
PubMed
- Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma.Fleming, S., Gifkins, D., Resnick, H., Rosenberg, P., Gaj, C., Maio, V., Crawford, A., Lu-Yao, G., Shalaby, W., Gao, J., Siefker-Radtke, A.> ;Clinical Genitourinary Cancer. 2024 Feb 15
- A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma.Msaouel, P., Sweis, R., Bupathi, M., Heath, E., Goodman, O., Hoimes, C., Milowsky, M., Davis, N., Kalebasty, A., Picus, J., Shaffer, D., Mao, S., Adra, N., Yorio, J., ...> ;European Urology Oncology. 2023 Dec 16
- Evolution of front-line immunotherapy for metastatic urothelial cancer.Siefker-Radtke, A., Desai, M.> ;The Lancet. Oncology. 2024 Jan 1
- Join now to see all
Lectures
- Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update from CheckMate 275.2019 ASCO Annual Meeting - 6/1/2019
- FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary anal...2019 ASCO Annual Meeting - 6/1/2019
- Tailoring of Chemotherapy to Fit Patients With Metastatic Urothelial Cancer2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
- Join now to see all
Press Mentions
- NCCN Clinical Practice Guidelines in Oncology: 2023 UpdatesMay 19th, 2023
- Can Frequent UTIs Be a Sign of Bladder Cancer?March 9th, 2023
- Neoadjuvant Chemotherapy Shows “Clear Benefit” in Upper Tract Urothelial CarcinomaJanuary 26th, 2023
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: